Lipella Financial Statements From 2010 to 2026

LIPO Stock   0.18  0.01  5.26%   
Lipella Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lipella Pharmaceuticals' valuation are provided below:
Gross Profit
-3.4 M
Market Capitalization
2.4 M
Enterprise Value Revenue
0.1499
Revenue
470.2 K
Earnings Share
(3.33)
We have found one hundred twenty available fundamental ratios for Lipella Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipella Pharmaceuticals' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 3rd of January 2026, Market Cap is likely to grow to about 4.2 M, while Enterprise Value is likely to drop about 906 K.

Lipella Pharmaceuticals Total Revenue

411,454

Check Lipella Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipella Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 K, Interest Expense of 0.0 or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 5.1, Dividend Yield of 0.0 or PTB Ratio of 1.57. Lipella financial statements analysis is a perfect complement when working with Lipella Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Lipella Stock
Check out the analysis of Lipella Pharmaceuticals Correlation against competitors.

Lipella Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.8 M3.1 M1.3 M
Slightly volatile
Short and Long Term Debt Total40.7 K42.8 K139.4 K
Pretty Stable
Other Current Liabilities235.6 K366.4 K146.1 K
Slightly volatile
Total Current Liabilities555.9 K867.6 K349.8 K
Slightly volatile
Other Liabilities28.6 K34.9 K25.1 K
Slightly volatile
Accounts Payable468.7 K446.4 K140.6 K
Slightly volatile
Cash2.3 M2.5 MM
Slightly volatile
Cash And Short Term Investments2.4 M2.5 M1.1 M
Slightly volatile
Net Receivables61.4 K76.2 K81.8 K
Pretty Stable
Common Stock Shares Outstanding1.3 M1.2 M474.7 K
Slightly volatile
Liabilities And Stockholders Equity2.8 M3.1 M1.3 M
Slightly volatile
Other Current Assets209.2 K399.8 K107.7 K
Slightly volatile
Other Stockholder Equity20.8 M19.8 M5.8 M
Slightly volatile
Total Liabilities693 K867.6 K439.8 K
Slightly volatile
Total Current Assets2.7 MM1.2 M
Slightly volatile
Short Term Debt52 K54.7 K74.8 K
Slightly volatile
Common Stock103109451
Slightly volatile
Property Plant And Equipment Net48.4 K51 K204.2 K
Slightly volatile
Current Deferred Revenue112.2 K205.8 K77 K
Slightly volatile
Non Current Assets Total48.4 K51 K204.2 K
Slightly volatile
Long Term Debt40 K45 K49.1 K
Slightly volatile
Capital Lease Obligations40.7 K42.8 K203.3 K
Slightly volatile
Net Invested Capital2.7 M2.2 M1.3 M
Slightly volatile
Property Plant And Equipment Gross171.8 K168.3 K233.5 K
Slightly volatile
Short and Long Term Debt332.1 K316.2 K141.2 K
Slightly volatile
Capital Stock132139635
Slightly volatile
Net Working Capital2.5 M2.1 M1.2 M
Slightly volatile
Property Plant Equipment163 K135.7 K221.6 K
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile

Lipella Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.2 K3.3 K300.7 K
Pretty Stable
Selling General Administrative2.4 M2.3 M619.3 K
Slightly volatile
Total Revenue411.5 K482.7 K601.9 K
Slightly volatile
Other Operating Expenses6.8 M6.5 M2.2 M
Slightly volatile
Research Development2.3 M4.2 M1.5 M
Slightly volatile
Cost Of Revenue2.3 M4.2 M1.5 M
Slightly volatile
Total Operating Expenses2.4 M2.3 M619.3 K
Slightly volatile
Interest Income77.6 K73.9 K20.6 K
Slightly volatile
Selling And Marketing Expenses1.7 B1.9 B2.1 B
Slightly volatile

Lipella Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.9 M3.8 M975.1 K
Slightly volatile
Total Cash From Financing Activities2.2 M3.3 M1.1 M
Slightly volatile
End Period Cash Flow2.3 M2.5 MM
Slightly volatile
Change To Netincome914.1 K870.6 K287.3 K
Slightly volatile
Stock Based Compensation800.4 K861.8 K345.7 K
Slightly volatile
Issuance Of Capital Stock2.7 M3.3 M1.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.15.367.7923
Slightly volatile
Days Sales Outstanding60.751.8865.5241
Slightly volatile
Average Payables155.4 K236.8 K103.2 K
Slightly volatile
Stock Based Compensation To Revenue1.821.260.8835
Slightly volatile
Capex To Depreciation0.00110.00127.0547
Slightly volatile
EV To Sales1.691.785.0277
Pretty Stable
Payables Turnover10.1710.715.7681
Very volatile
Sales General And Administrative To Revenue1.693.361.0924
Slightly volatile
Research And Ddevelopement To Revenue4.666.063.2065
Slightly volatile
Capex To Revenue0.00.00.0264
Slightly volatile
Cash Per Share3.021.881.672
Slightly volatile
Days Payables Outstanding21.0935.2926.5818
Pretty Stable
Income Quality0.50.710.6296
Very volatile
Current Ratio3.563.122.3425
Slightly volatile
Receivables Turnover9.77.288.072
Very volatile
Capex Per Share0.00.00.0159
Slightly volatile
Average Receivables44.6 K52.6 K41.2 K
Slightly volatile
Revenue Per Share0.560.591.9712
Slightly volatile
Interest Debt Per Share0.04960.05220.4405
Pretty Stable
Debt To Assets0.01950.02050.5368
Slightly volatile
Operating Cycle60.751.8865.5241
Slightly volatile
Days Of Payables Outstanding21.0935.2926.5818
Pretty Stable
Ebt Per Ebit1.131.141.1053
Slightly volatile
Quick Ratio3.563.122.3425
Slightly volatile
Net Income Per E B T1.141.151.0672
Pretty Stable
Cash Ratio3.072.611.7712
Slightly volatile
Days Of Sales Outstanding60.751.8865.5241
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9864
Slightly volatile
Fixed Asset Turnover8.958.534.3452
Slightly volatile
Debt Ratio0.01950.02050.5368
Slightly volatile
Price Sales Ratio5.15.367.7923
Slightly volatile
Asset Turnover0.220.233.5509
Slightly volatile

Lipella Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.2 M2.9 M2.9 M
Slightly volatile
Enterprise Value906 K953.7 K1.9 M
Pretty Stable

Lipella Fundamental Market Drivers

Lipella Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Lipella Pharmaceuticals Financial Statements

Lipella Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Lipella Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue205.8 K112.2 K
Total Revenue482.7 K411.5 K
Cost Of Revenue4.2 M2.3 M
Stock Based Compensation To Revenue 1.26  1.82 
Sales General And Administrative To Revenue 3.36  1.69 
Research And Ddevelopement To Revenue 6.06  4.66 
Revenue Per Share 0.59  0.56 
Ebit Per Revenue(10.89)(11.44)

Pair Trading with Lipella Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipella Stock

  0.92FTV Fortive CorpPairCorr
  0.88BAC Bank of AmericaPairCorr
  0.84AXP American ExpressPairCorr
  0.83MRK Merck CompanyPairCorr
  0.82CAT CaterpillarPairCorr
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock:
Check out the analysis of Lipella Pharmaceuticals Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.33)
Revenue Per Share
0.216
Quarterly Revenue Growth
(0.36)
Return On Assets
(1.18)
Return On Equity
(2.48)
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.